ClinicalTrials.Veeva

Find clinical trials for Chronic Lymphocytic Leukemia in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Mantle-Cell Lymphoma
Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia trials near London, England, GBR:

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic le...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

London, United Kingdom and 11 other locations

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib
Drug: Ibrutinib

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

London, London, City Of, United Kingdom and 27 other locations

This study evaluates the safety, pharmacokinetics, pharmacodynamics and efficacy of acalabrutinib and ceralasertib (known as AZD6738) when taken in c...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Ceralasertib
Drug: Acalabrutinib

Phase 1

Acerta Pharma
Acerta Pharma

London, United Kingdom and 10 other locations

This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Ibrutinib
Drug: Acalabrutinib

Phase 3

Acerta Pharma
Acerta Pharma

London, United Kingdom and 130 other locations

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Enrolling
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Phase 3

Loxo Oncology
Loxo Oncology

London, London, City Of, United Kingdom and 179 other locations

study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lympho...

Enrolling
Small Lymphocytic Lymphoma
Relapsed/Refractory Chronic Lymphocytic Leukemia
Drug: Venetoclax
Biological: Epcoritamab

Phase 1, Phase 2

Genmab
Genmab

London, United Kingdom and 74 other locations

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...

Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Obinutuzumab
Drug: Venetoclax

Phase 3

Janssen (J&J Innovative Medicine)

Romford, United Kingdom and 85 other locations

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Idelalisib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

London, Greater London, United Kingdom and 231 other locations

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in partici...

Active, not recruiting
Lymphocytic Leukemia, Chronic
Lymphoma, Non Hodgkin
Drug: BTCT4465A (Mosunetuzumab) IV
Drug: BTCT4465A (Mosunetuzumab) SC

Phase 1, Phase 2

Genentech
Genentech

London, United Kingdom and 48 other locations

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination wit...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Obinutuzumab

Phase 3

Acerta Pharma
Acerta Pharma

Cambridge, United Kingdom and 170 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems